These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8142153)

  • 1. Dose optimisation and dose intensification in malignant lymphoma.
    Linch DC
    Eur J Cancer; 1994; 30A(1):122-5. PubMed ID: 8142153
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.
    Canellos GP
    Ann Oncol; 1994; 5 Suppl 2():121-2. PubMed ID: 8204512
    [No Abstract]   [Full Text] [Related]  

  • 3. The importance of dose: lymphomas as a model of chemosensitive malignancies.
    Bronchud MH
    Eur J Cancer; 1993; 29A Suppl 5():S17-22. PubMed ID: 8260261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematopoietic growth factors in clinical medicine.
    Henschler R; Brugger W; Kanz L; Mertelsmann R
    Eur J Cancer; 1994; 30A(1):118-9. PubMed ID: 7511397
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
    Liem GS; Verweij J
    Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intensive therapy for small cell lung cancer.
    Elias AD
    Chest; 1995 Jun; 107(6 Suppl):261S-266S. PubMed ID: 7781403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors.
    Trillet-Lenoir V; Arpin D; Brune J
    Eur J Cancer; 1993; 29A Suppl 5():S14-6. PubMed ID: 8260260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose optimisation and intensification of cytotoxics in solid tumours supported by haematopoietic growth factors.
    Le Chevalier T
    Eur J Cancer; 1994; 30A(3):410-2. PubMed ID: 8204370
    [No Abstract]   [Full Text] [Related]  

  • 10. [Relation dose efficacy in chemotherapy: the example of breast cancer].
    Chevallier B; Perrocheau G
    Bull Cancer; 1995; 82 Suppl 1():9s-15s. PubMed ID: 7626858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of hematopoietic growth factors.
    Seipelt G
    Antibiot Chemother (1971); 2000; 50():94-105. PubMed ID: 10874458
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of dose and schedule in cancer chemotherapy: haematological cancer.
    Sweetenham JW
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():7-15. PubMed ID: 8845497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma.
    Avilés A; Guzmán R; Delgado S; Nambo MJ; García EL; Díaz-Maqueo JC
    Am J Hematol; 1996 Aug; 52(4):275-80. PubMed ID: 8701945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use].
    Paul C; Hast R
    Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hematopoietins: a new agent for the treatment of hemopoietic insufficiency].
    Gerrmann F; Lindemann A; Mertelsmann R
    Gematol Transfuziol; 1990 Sep; 35(9):24-6. PubMed ID: 2272449
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematopoietic growth factors in breast cancer--overview.
    Osborne CK
    Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S1-2. PubMed ID: 1806028
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical use of hematopoietic growth factors in treatment of bone marrow failure].
    Robak T; Krykowski E
    Pol Arch Med Wewn; 1994 Jul; 92(1):1-8. PubMed ID: 7971472
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term perspective of hematologic malignancies.
    Cheson BD
    Trans Assoc Life Insur Med Dir Am; 1988; 71():198-220. PubMed ID: 3285568
    [No Abstract]   [Full Text] [Related]  

  • 20. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
    Coiffier B
    J Clin Oncol; 2003 Jul; 21(13):2457-9. PubMed ID: 12829662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.